Analytical Platform for Rapid, Reliable mRNA Modality Analytics

The rapid evolution of messenger RNA (mRNA) based therapies and vaccines demands analytical workflows that are both highly reliable and adaptable to diverse modality-specific requirements. As vaccine constructs and therapeutic transcripts diversify in size, structure and lipid nanoparticle formulations, there is a growing need for an analytic platform that delivers consistent, high‐quality data without sacrificing agility. Traditional assay pipelines often struggle to balance throughput, sensitivity and flexibility, leading to delays in development timelines and potential gaps in quality control.

This webinar will examine the design and implementation of a modular analytical platform engineered for rapid deployment across varying mRNA applications, from prophylactic vaccine candidates to long-acting therapeutic constructs. The featured speakers will highlight how the platform is not only customizable but also accelerates early-stage screening and process optimization. Additionally, the platform supports scalable, regulatory-compliant analytics as candidates advance toward clinical and commercial phases. The assay parameters can be tailored to meet the specific demands of vaccines, transient therapeutics or long‐duration mRNA constructs.

Overall, this adaptable approach accelerates the development and validation process by streamlining assay deployment and reducing setup time. As the field of mRNA therapeutics continues to expand, a robust and flexible analytical platform will be essential for translating innovative modalities into safe, effective products that reach patients more quickly.

Register for this webinar to learn how a flexible analytical platform supports rapid, reliable analytics for evolving mRNA modalities.

Speakers

Jeff Heiser, CSO of Microbial and Advanced Therapeutic Platforms, BA Sciences

Jeff Heiser is the Chief Scientific Officer (CSO) of Microbial and Advanced Therapeutic Platforms at Boston Analytical. After graduating from the University of New Hampshire with a degree in Microbiology Research in 2007, he entered the industry working for Pfizer Biologics at their site in Andover, MA. There, he worked on rapid microbiological methods for multivalent vaccines and biologic products. Following Pfizer, Jeff joined Genzyme Biosurgery in direct support of autologous knee cartilage and skin graft products.

Read more...

In 2012, Jeff joined Boston Analytical, where he worked his way to becoming the Director of Microbiology, growing the lab in support of release testing and environmental monitoring. In 2020, Jeff joined Arranta Bio, a CDMO, leading their analytical development and process science efforts in live biotherapeutic products (LBP), plasmid DNA (pDNA) and mRNA modalities. In 2023, Jeff rejoined the Boston Analytical team as the Chief Scientific Officer to lead the scientific thought leadership initiatives on microbiological and advanced therapeutic platforms. Advanced therapeutics included not only LBP but also pDNA, mRNA and gene therapy modalities. Jeff’s primary focus in the coming months will be to advance our microbiome expertise and to roll out a comprehensive analytical solution for our mRNA platform clients.

Read Less...

Message Presenter

Alaknanda Mishra, PhD, Director of Advanced Therapeutics, BA Sciences

Alaknanda Mishra, PhD, is the Director of Advanced Therapeutics at BA Sciences. Dr. Alaknanda Mishra is an accomplished scientific leader with extensive experience in developing and advancing cutting-edge biologics, including mRNA therapeutics, gene and cell therapies and exosome platforms. With a strong foundation in cell biology and immunology, she has led cross-functional teams across R&D, analytical development and preclinical operations to drive innovation from early research through translational readiness.

Read more...

Her expertise spans analytical development, bioanalysis, immunoassays and preclinical research, backed by a robust publication record in cell and gene therapy. Dr. Mishra holds a PhD in Cell Biology and Immunology from the National Institute of Immunology, India, and completed her postdoctoral training at the University of California, Davis, and the National Institute of Health in Dr. Paul Sieving’s lab. She combines deep technical knowledge with strategic acumen, having also worked in various biotech startups such as Mantra Bio, Chameleon Bio and Vernal Biosciences in numerous capacities, guiding scientific and CMC strategy. Her leadership has consistently bridged scientific rigor with regulatory goals, enabling successful execution of novel therapeutic programs in fast-paced biotech environments.

Read Less...

Message Presenter